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Summary
The endocannabinoid system can modulate energy homeostasis
by regulating feeding behaviour as well as peripheral energy
storage and utilization. Importantly, many of its metabolic actions
are mediated through the cannabinoid type 1 receptor (CB1R),
whose hyperactivation is associated with obesity and impaired
metabolic function. Herein, we explored the effects of adminis-
tering rimonabant, a selective CB1R inverse agonist, upon key
metabolic parameters in young (4 month old) and aged (17 month
old) adultmale C57BL/6mice. Daily treatmentwith rimonabant for
14 days transiently reduced food intake in young and aged mice;
however, the anorectic response was more profound in aged
animals, coinciding with a substantive loss in body fat mass.
Notably, reduced insulin sensitivity in aged skeletal muscle and
liver concurred with increased CB1R mRNA abundance. Strikingly,
rimonabantwas shown to improve glucose tolerance and enhance
skeletal muscle and liver insulin sensitivity in aged, but not young,
adult mice. Moreover, rimonabant-mediated insulin sensitization
in aged adipose tissue coincided with amelioration of low-grade
inflammation and repressed lipogenic gene expression. Collec-
tively, our findings indicate a key role for CB1R in aging-related
insulin resistance and metabolic dysfunction and highlight CB1R
blockade as a potential strategy for combating metabolic disor-
ders associated with aging.
Key words: aging; cannabinoid receptor type 1; insulin
resistance; rimonabant.
Introduction
Insulin plays a prominent role in the modulation of glucose homeostasis
and energy metabolism. Consequently, impaired responsiveness to
insulin, termed insulin resistance, is a key component of the metabolic
syndrome and a prelude to type 2 diabetes mellitus (T2DM). Importantly,
a number of studies have now linked aging with development of insulin
resistance in rodents as well as obese and nonobese individuals (Rowe
et al., 1983; O’Shaughnessy et al., 1992). However, those factors which
contribute to aging-related insulin resistance and metabolic dysfunction
remain poorly understood.
Initiation of insulin-induced signalling stems from the activated
insulin receptor kinase which can bind and regulate a number of
downstream intracellular targets, including the insulin receptor
substrate (IRS) family of proteins and phosphatidylinositol 3 kinase
(PI3K) (Johnston et al., 2003). The subsequent PI3K-mediated gener-
ation of phosphatidylinositol-(3,4,5)-triphosphate (PIP3) promotes
translocation of protein kinase B (PKB, also known as Akt) to the
plasma membrane where it undergoes phosphorylation/activation by
upstream kinases at its two key regulatory sites, Thr308 and Ser473
(of PKBa/Akt1), respectively. Activated PKB/Akt stimulates glycogen
synthesis and GLUT-dependent glucose uptake by phosphorylating
and inactivating GSK3 (glycogen synthase kinase 3) and the Rab
GTPase-activating protein AS160 (Akt substrate of 160 kDa), respec-
tively (Cross et al., 1995; Sano et al., 2003). Proper regulation of
these cellular processes is therefore crucial for maintaining glucose
homeostasis by controlling glucose storage and utilization.
Growing evidence indicates that the endocannabinoid system (ECS) is
intimately involved in the physiological control of food intake and energy
expenditure, through its ability to target central and peripheral sites
including skeletal muscle, liver and adipose tissue (Pagotto et al., 2006).
Many of the biological actions of the ECS are mediated through
G-protein-coupled cannabinoid type 1 (CB1R) and type 2 (CB2R)
receptors which can be activated by several endogenous ligands,
including anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Impor-
tantly, ECS dysregulation has been linked to abdominal obesity and
other risk factors for type 2 diabetes (Engeli et al., 2005; Osei-Hyiaman
et al., 2005; Matias et al., 2006). For example, genetic and diet-induced
obese animal models display elevated endocannabinoid levels in the
hypothalamus and peripheral tissues (Di Marzo et al., 2001; Osei-
Hyiaman et al., 2005; Matias et al., 2006). Furthermore, increased
circulating levels of AEA and 2-AG, as well as elevated levels of 2-AG
within visceral adipose tissue, have been reported in obese and/or
hyperglycaemic type 2 diabetic patients (Bluher et al., 2006; Matias
et al., 2006). In accord with this, hyperactivation of CB1R-induced
signalling has been implicated in numerous metabolic abnormalities
including hyperphagia, insulin resistance, glucose intolerance and
impaired lipid homeostasis (Engeli et al., 2005; Jbilo et al., 2005; Osei-
Hyiaman et al., 2005). Conversely, genetic or pharmacological CB1R
blockade improves metabolic status, for example by promoting reduc-
tions in body weight and fat mass, as well as enhancing insulin sensitivity
and glucose tolerance. Indeed, these beneficial responses may be
mediated through central appetite suppression and/or through direct
modulation of peripheral energy metabolism (Bensaid et al., 2003;
Ravinet Trillou et al., 2003, 2004; Jbilo et al., 2005; Pagotto et al., 2006;
Osei-Hyiaman et al., 2008; Jourdan et al., 2010).
Despite advances in our understanding of metabolic regulation by
the ECS, as well as previous reports of age-related deregulation of
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cannabinoid receptors and endocannabinoid hydrolysing enzymes
(Pascual et al., 2013, 2014), little is known regarding the involvement
of this signalling system in aging-associated metabolic dysfunction.
Herein, we explored the effects of chronic (14 day) administration of
rimonabant (SR141716), a potent and selective CB1R inverse agonist
(Landsman et al., 1997), on the energy budgets of young (4 month
old) and aged (17 month old) adult male mice. Physical activity (PA)
and body temperature (Tb) were monitored throughout the 14-day
experiment using implanted transmitters, and resting metabolic rate
(RMR) by indirect calorimetry. This protocol permitted investigation of
the effects of chronic rimonabant treatment upon different compo-
nents of energy intake and expenditure, as well as body weight and
fat mass. In addition, the impact of rimonabant upon key metabolic
signalling pathways was determined in skeletal muscle, adipose tissue
and liver isolated from young and aged mice. We show that aging
was associated with a marked reduction in skeletal muscle and liver
insulin sensitivity, which coincides with increased body fat mass.
Intriguingly, this aging-related insulin desensitization concurred with
increased muscle and hepatic CB1R gene expression, indicative of
enhanced endocannabinoid/CB1R tone within these tissues. Strikingly,
rimonabant improved insulin sensitivity and glucose tolerance in aged,
but not young, adult mice. Moreover, CB1 blockade induced a
marked loss in body fat mass, concomitant with its ability to reduce
adipogenic capacity and counteract low-grade inflammation in aged
epididymal fat tissue. Together, our findings reveal a novel role for the
ECS in aging-related metabolic dysfunction and identify CB1R as a
potential therapeutic target in the treatment of metabolic disorders
associated with the aging process.
Results
The anorectic and weight reducing effects of rimonabant are
more profound in aged versus young adult C57BL/6 mice
Rimonabant treatment significantly reduced daily food consumption in
young mice from day 2 (2.5  0.11 g to 1.8  0.13 g; P < 0.05)
until day 4 (2.5  0.08 g to 2.1  0.08 g; P < 0.05) of the treatment
period (Fig. 1A). No significant differences in food intake were
observed in response to the CB1R blocker in young mice for the
remainder of the 14-day study period. Strikingly, rimonabant triggered
a more profound and prolonged decrease in daily food consumption
in aged mice (Fig. 1B), including a marked reduction from
2.7  0.22 g to 0.51  0.09 g (P < 0.05) at treatment day 3. This
preceded a more protracted recovery period, whereby daily food
intake was significantly reduced until day 10, excluding treatment
days 7 and 9. It should be noted that the observed reduction in food
consumption in young and aged control-treated mice on days 10 and
11 was likely attributable to the fasting period which preceded the
glucose tolerance test on day 11. In accord with its more robust
anorectic response in aged mice, rimonabant also promoted a greater
reduction in total body mass in aged animals compared to younger
counterparts (Fig. 1C). Corresponding statistical analysis of the AUC
(area under the curve) revealed a significant 8.5% decrease in the
AUC representing aged animals treated with rimonabant versus
control, compared to the 3.5% (not significant) reduction in AUC
mediated by CB1R blockade in young mice (Fig. 1D). It should be
noted that there were no significant differences between vehicle
control and rimonabant treatment groups at baseline in both young
and aged mice.
Rimonabant does not alter parameters of energy expenditure
in young and aged mice
Next, we explored the possibility that the observed reductions in body
mass in response to rimonabant may also be associated with increased
systemic energy expenditure (Zhang et al., 2012). For example, rimon-
abant has been previously reported to increase energy expenditure in
diet-induced obese C57BL/6 mice (Zhang et al., 2012). However as
shown in Fig. 2, neither physical activity (Fig. 2A and B), body
temperature (Fig. 2C and D) or resting metabolic rate (RMR) (Fig. 2E
and F), were significantly altered by rimonabant treatment in young and
aged mice. The hyperactivity on days 10 or 11 coincided with removing
the food prior to performing the GTT. Therefore, these data indicate that
it is unlikely that CB1R blockade promotes reductions in body weight
through altering energy expenditure in young or aged mice.
Aging-related insulin resistance in skeletal muscle and liver
coincides with increased CB1R gene expression
Numerous studies have linked aging with development of insulin
resistance (Rowe et al., 1983; O’Shaughnessy et al., 1992; Sczelecki
et al., 2013). In accord with this, we report a marked reduction in the
ability of insulin to phosphorylate/activate PKB at its two key regulatory
sites Thr308 (by 1.7-fold; P < 0.05) and Ser473 (by 1.6 fold; P < 0.05) in
aged versus young soleus tissue (Fig. 3A). In addition, aged gastrocne-
mius muscle also displayed a significant 1.7-fold decrease in insulin-
induced PKB/Akt473 phosphorylation relative to tissue from younger mice
(Fig. 3B). Strikingly, this aging-related impairment in insulin sensitivity
coincided with a 1.8-fold (P < 0.05) increase in CB1R mRNA abundance
in aged versus young gastrocnemius muscle, in contrast to the 1.3-fold
(P < 0.05) decrease in CB2R mRNA (Fig. 3C). In addition, analysis of
respective liver samples similarly revealed a significant 1.7-fold reduction
in insulin-induced PKB473 phosphorylation in aged versus young tissue
(Fig. S1A), concurring with a marked 3.8-fold (P < 0.05) increase in
hepatic CB1R gene expression (Fig. S1B). Therefore, these data indicate
that impaired insulin action in aged skeletal muscle and liver is associated
with enhanced ECS/CB1R tone.
Rimonabant improves insulin sensitivity and glucose
tolerance in aged but not young mice
Based on our observation that reduced insulin sensitivity in skeletal
muscle and liver concurs with enhanced ECS/CB1R tone, we hypothe-
sized that CB1R antagonism may act to ameliorate aging-related insulin
desensitization. Strikingly, rimonabant treatment significantly enhanced
insulin-stimulated PKB/Akt308 and PKB/Akt473 phosphorylation by 3-fold
and 1.5-fold respectively, in aged soleus muscle (Fig. 4B), but not in solei
of younger mice (Fig. 4A). Moreover, treatment with the CB1R blocker
also augmented insulin-induced PKB/Akt473 phosphorylation (by 1.8-
fold; P < 0.05) in aged gastrocnemius muscle (Fig. S2).
Allied to its insulin-sensitizing action within aged skeletal muscle,
rimonabant also significantly enhanced insulin-stimulated PKB/Akt473
phosphorylation (by 1.8 fold) in aged livers, in contrast to conveying a
slight repressive (although not significant) effect in hepatic tissue from
younger mice (compare Fig. S3A and B). Importantly, in accord with
these improvements in insulin-induced signalling in aged skeletal muscle
and liver, we further report enhanced glucose tolerance in aged mice
administered rimonabant, as determined by GTT (Fig. 4D). Intriguingly,
this improvement in glucose tolerance was not manifested in younger
mice treated with the inverse CB1R agonist (Fig. 4C). Statistical analysis
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revealed an 11% decrease in the AUC representing aged animals treated
with rimonabant versus control (P < 0.05), compared to the 3.4% (not
significant) reduction in response to CB1R blockade in younger mice
(Fig. 4E). Moreover, this rimonabant-mediated improvement in glucose
tolerance coincided with the partial (~50%) normalization of fasting
plasma insulin levels, which were found to be 3.8-fold (P < 0.05) higher
in aged versus young mice (Fig. S5A). Together, these findings indicate
enhanced insulin sensitivity following rimonabant administration in aged
mice, and reveal age-dependent effects of CB1R inhibition upon insulin
action and systemic glucose homeostasis.
Rimonabant downregulates abundance of the catalytic
subunit of PP2A in skeletal muscle
In an attempt to elucidate the mechanism(s) by which rimonabant acts
to improve insulin sensitivity, we first explored the possibility that CB1R
blockade may function by positively modulating upstream insulin
receptor signalling. However, as shown in Fig. 5A, administration of
rimonabant did not alter protein abundance of the insulin receptor b
subunit, IRS-1, PTEN, or the p85 regulatory subunit of PI3K in aged
gastrocnemius muscle. Moreover, CB1R inhibition did not significantly
alter phosphorylation of IRS-1 at Ser307 (Fig. 5B), a site whose
phosphorylation in response to CB1R activation has been associated
with suppressed IRS-1/PKB dependent signalling (Liu et al., 2012).
Indeed, this is consistent with our previous work demonstrating the
ability of rimonabant to enhance insulin sensitivity in rat L6 myotubes, an
in vitro skeletal muscle model, without altering upstream IRS-1/PI3K
signalling (Lipina et al., 2010). Therefore, we next focussed on
alternative pathways involving the potential modulation of PHLPP1 and
PP2A (protein phosphatase 2A), two key negative regulators which act
to dephosphorylate and inactivate PKB/Akt (Resjo et al., 2002; Liu et al.,
2012). Rimonabant treatment did not alter levels of PHLPP1 protein in
aged gastrocnemius muscle (Fig. 5A) but did, however, promote a
significant 1.8-fold reduction in the protein abundance of the PP2A
catalytic subunit (PP2Ac) in the same tissue (Fig. 5C). Notably, we also
observed a modest (1.3-fold) increase in PP2Ac protein abundance in
gastrocnemius muscle of aged versus young mice, although this was not
found to be significant (Fig. 5D). Allied to these observations in vivo, we
further demonstrate that the ability of the selective CB1R agonist ACEA
to inhibit insulin-induced PKB/Akt308 phosphorylation in L6 myotubes is
completely prevented by co-treatment with either rimonabant or
okadaic acid, a potent PP2A inhibitor (Fig. 5E). Together, these data
implicate PP2A as a key component in CB1R-induced insulin resistance,
whereby its repression in response to CB1R blockade may serve to
alleviate its inhibitory action towards PKB/Akt.
Rimonabant conveys anti-adipogenic and anti-inflammatory
effects in aged epididymal fat tissue
It is now widely acknowledged that obesity increases the risk of
developing insulin resistance (Everhart et al., 1992). In accord with this,
our DXA analysis revealed that body fat mass of aged mice was 2.3-fold
(P < 0.05) higher in comparison to their younger counterparts (Fig. 6A).
Intriguingly, rimonabant treatment in aged mice led to a 1.5-fold
(P < 0.05) reduction in body fat mass, but exhibited no significant effect
in younger animals (Fig. 6A). Consistent with its observed anti-obesity
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Fig. 1 Changes in Food Intake and Body
Weight of Male C57BL/6 Mice in Response
to Rimonabant Administration. Mean daily
food intake (A, B) and body mass (C, D) of
young (A, C) and aged (B, D) C57BL/6 mice
treated with rimonabant (Rim) or vehicle
control (Con) in the absence and presence
of insulin were monitored over a 14-day
period as shown. All values presented are
the mean  SEM from 15 mice. Asterisks
denote statistically significant differences
between vehicle control and SR141716
treated. *P < 0.05, ANOVA.
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action in older mice, rimonabant markedly decreased mRNA levels of the
lipogenic gene fatty acid synthase (FAS) by 4-fold (P < 0.05) in aged
epididymal fat tissue (Fig. 6B). However, there was a tendency for
rimonabant to reduce mRNA abundance of SREBP-1 (sterol regulatory
element binding protein -1), a transcriptional regulator of FAS, as well as
the pro-adipogenic gene PPARc2 (peroxisome proliferator-activated
receptor c), although the effects were not significant in each case
(Fig. 6B). In addition, rimonabant treatment significantly induced mRNA
abundance of the lipolytic enzyme ATGL (adipose triglyceride lipase) by
1.9-fold (P < 0.05) (Fig. 6B). Therefore, these data indicate that CB1R
blockade may act to reduce body fat in aged mice, at least in part, by
impairing and/or inducing pro-adipogenic and lipolytic processes,
respectively.
Because adipose tissue is a key site for production and secretion of
insulin-desensitizing pro-inflammatory cytokines, we subsequently
explored the possibility that rimonabant may convey anti-inflammatory
actions within this tissue (Wang et al., 2011). As shown in Fig. 6C, we
report a 1.5-fold (P < 0.05) increase in the protein abundance of IjBa
(Inhibitory Subunit of NF Kappa B alpha), a key repressor of NF-jB-driven
pro-inflammatory cytokine gene expression, within epididymal fat tissue
of aged mice treated with rimonabant (Fig. 6C). Accordingly, this
coincided with a significant 1.4-fold reduction in the mRNA abundance
of IL-6 (Interleukin-6), an established NF-jB target gene (Fig. 6D), as well
as a 1.3-fold (P < 0.05) decrease in plasma IL-6 levels (Fig. S5B).
Moreover, in accord with its anti-inflammatory response, rimonabant
treatment was found to almost completely suppress protein abundance
of the macrophage marker CD68 in aged epididymal fat tissue, indicative
of reduced macrophage infiltration (Fig. S4). Notably, rimonabant has
also been reported to increase expression of adiponectin, an insulin-
sensitizing adipokine, in adipose tissue of obese fa/fa rats and in cultured
3T3 F442A adipocytes (Bensaid et al., 2003). In accord with this, we
demonstrate a significant 1.2-fold (P < 0.05) increase in plasma levels of
adiponectin following rimonabant treatment in aged mice (Fig. S5C).
Therefore, the ability of CB1R antagonism to counteract low-grade
inflammation and/or increase levels of adiponectin may, at least in part,
contribute to its insulin-sensitizing action in aged epididymal fat, as
demonstrated by the 1.5-fold (P < 0.05) augmentation in insulin-
induced PKB308 phosphorylation (Fig. 6E). Importantly, these findings
indicate anti-adipogenic, pro-lipolytic and anti-inflammatory actions
conveyed by rimonabant within aged adipose tissue which may, at least
in part, underlie its ability to improve systemic insulin sensitivity and
glucose tolerance in older mice.
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Fig. 2 Effects of Rimonabant
administration on Key Indicators of Energy
Expenditure in Young and Aged Mice.
Young and aged adult male C57BL/6 mice
treated with rimonabant (Rim) or vehicle
control (Con) had their physical activity (A,
B) and body temperature (C, D) monitored
daily during the 14-day study period as
indicated. Mean resting metabolic rates
(RMR) determined on day 9 of the study are
also shown (E, F). All values presented are
the mean  SEM from 15 individual
animals. NS, not significant, ANCOVA.
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Discussion
A number of animal studies and clinical trials have previously described
the anti-obesity and insulin-sensitizing effects of CB1R antagonism
(Ravinet Trillou et al., 2003; Jbilo et al., 2005; Alonso et al., 2011). This
study reveals for the first time, a protective role for CB1R inhibition
against aging-related metabolic dysfunction in mice. We report that
rimonabant improves insulin sensitivity and glucose tolerance in aged
mice, whereas the CB1R blocker failed to convey these same beneficial
responses in younger animals. This coincided with the ability of
rimonabant to induce a more profound anorectic response and greater
reduction in body fat mass in older mice. Crucially, we demonstrate
increased CB1R gene expression in aged skeletal muscle and liver,
indicative of enhanced endocannabinoid/CB1R tone in response to
aging. Notably, our findings are consistent with previous work reporting
high fat diet-induced increases in CB1R tissue expression in younger
animals, together with the amelioration of dyslipidaemia and lipogen-
esis, as well as improved insulin sensitivity in mice deficient for CB1R
(Osei-Hyiaman et al., 2008). Indeed, it is possible that the improvements
in insulin sensitivity that are conveyed by rimonabant in aged mice may
be due, at least in part, to reductions in adiposity. However, it should be
noted that previous studies utilizing hyperinsulinaemic-euglycaemic
clamps and/or ITT (insulin tolerance test), have documented the ability of
rimonabant to improve insulin sensitivity without promoting significant
reductions in body fat mass or visceral fat in db/db mice and diet-induced
obese dogs, respectively (Kim et al., 2012; Nam et al., 2012). Together
with our previous work reporting direct insulin-sensitizing actions by
rimonabant in rat skeletal L6 myotubes (Lipina et al., 2010), these
findings indicate that CB1R inhibition may at least partly enhance
insulin sensitivity in aged mice independently of its ability to normalize
age-related adiposity.
Notably, rimonabant-mediated insulin sensitization in aged skeletal
muscle coincides with the ability of the CB1R blocker to repress
expression of the catalytic subunit of PP2A, a key negative regulator of
PKB/Akt (Andjelkovic et al., 1996). Moreover, pharmacological inhibition
of PP2A, similar to rimonabant provision, were both shown to prevent
CB1R-induced insulin desensitization in rat skeletal L6 myotubes. In
contrast, rimonabant treatment in aged mice failed to alter the
expression of several key upstream insulin signalling components. In
addition, we have previously reported the ability of rimonabant to
enhance insulin sensitivity in L6 myotubes without impacting upon IRS-1/
PI3K signalling (Lipina et al., 2010). Therefore, these findings indicate
that it is unlikely that CB1R blockade conveys its insulin-sensitizing
effects through modulating upstream signalling components, but
instead, acts to alleviate PP2A-mediated repression of PKB/Akt, at least
in skeletal muscle.
In accord with its insulin-sensitizing actions, the ability of rimonabant
to reduce body fat was markedly enhanced in aged mice. This may be
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Fig. 3 Aging-related Insulin Resistance in
Skeletal Muscle is Associated with Reduced
Insulin Sensitivity and Upregulated CB1R
Gene Expression. Lysates prepared from
Soleus (A) and Gastrocnemius muscle (B)
from young and aged mice stimulated with
or without insulin were immunoblotted
using phospho and native PKB/Akt
antibodies as indicated. n = 5 per group,
*P < 0.05, t-test. Alternatively, total RNA
extracted from noninsulin-treated
gastrocnemius muscle was used to
determine CB1R and CB2R mRNA
abundance by qPCR analysis (C). Relative
mRNA values presented are the
mean  SEM from 5 individual animals.
*P < 0.05, t-test.
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due, at least in part, to its more effective inhibition of food intake in
aged animals, although the exact processes underlying this anorectic
response remain unclear. One possible explanation may involve aging-
related increases in endocannabinoid/CB1R tone in regions of the brain
associated with appetite regulation, such as the nucleus accumbens
(Maldonado-Irizarry et al., 1995; Winters et al., 2012). Indeed, these
changes may be brought about by increased CB1R expression, or in
response to the altered activity of enzymes implicated in the synthesis
and/or degradation of endocannabinoids (Pascual et al., 2013). Conse-
quently, such a scenario may convey the apparent augmentation of
rimonabant’s anorectic response in older mice. Furthermore, CB1R
inhibition may counteract the appetite inducing effects of peptides such
as ghrelin, whose circulating levels have been shown to increase with
aging in mice (Senin et al., 2013; Lin et al., 2014).
CB1R blockade has also been shown to promote reductions in body
fat mass through direct peripheral actions in adipocytes (Jbilo et al.,
2005; Jourdan et al., 2010). In accord with this, we report the ability of
rimonabant to repress or induce lipogenic and lipolytic genes, respec-
tively, in aged epididymal fat tissue. Indeed, CB1R inhibition may act to
diminish aging-associated lipogenesis, a process known to be transduced
in response to CB1R activation, as well as promoting increased lipolytic
drive either directly or indirectly, for example through activation of the
sympathoadrenal system (Jbilo et al., 2005; Molhoj et al., 2010).
Furthermore, the anti-inflammatory response conveyed by the CB1R
blocker in aged epididymal fat may also contribute to its insulin-
sensitizing actions, in particular considering the fact that adipose tissue
serves as a key site for the production and secretion of insulin-
desensitizing inflammatory cytokines such as IL-6 and TNFa (Gnacinska
et al., 2009; Gustafson, 2010).
Notably, previous pair-feeding studies carried out in rodents have
revealed that the beneficial metabolic effects conveyed by chronic
(>1 week) pharmacological blockade of CB1R, or CB1R deficiency, may
arise through food intake dependent or independent (e.g. increased
energy expenditure) mechanisms (Cota et al., 2003; Jbilo et al., 2005;
Herling et al., 2008; Nogueiras et al., 2008). Whilst this present study
did not permit us to discriminate between these two different modes of
action directly, our findings indicate that rimonabant is unlikely to
convey its metabolic improvements in aged mice by increasing energy
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expenditure. Indeed, this was demonstrated by the lack of significant
change in several parameters of energy expenditure including physical
activity and resting metabolic rate following administration of the inverse
CB1R agonist. However, we cannot rule out the possibility that
rimonabant may act to enhance mitochondrial biogenesis and/or
oxidative capacity within individual tissues, thereby contributing to their
improved metabolic status (Jbilo et al., 2005; Tedesco et al., 2008).
Indeed, to support this possibility we report a 2.5-fold (P < 0.05)
increase in PGC-1a protein abundance in gastrocnemius muscle of aged
mice treated with rimonabant, although no such increase was observed
in aged epididymal fat tissue in response to CB1R inhibition (Fig. S6),
thereby suggesting tissue-specific actions. In an attempt to further
address this issue, future work comparing the metabolic effects of
rimonabant and peripherally acting CB1R antagonists (e.g. AM6545),
which display low blood brain barrier penetration, may help delineate
the relative contribution of hypophagic and peripherally targeted
responses conveyed by CB1R blockade (Tam et al., 2010). Indeed, such
studies may involve analysis of insulin signalling as well as utilizing
hyperinsulinaemic-euglycaemic clamps to assess insulin sensitivity in vivo.
In addition, our findings also raise the question as to whether
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rimonabant promotes its beneficial responses by functioning to inhibit
constitutive/tonic CB1R activity (i.e. inverse CB1R agonism), or alterna-
tively, by acting as a receptor antagonist (Bouaboula et al., 1997; Xie
et al., 2007). Follow up studies assessing the effects of CB1R stimulation
and/or inhibition upon metabolic processes in primary cells (i.e.
hepatocytes, muscle cells and adipocytes) isolated from young and aged
animals, may prove useful in identifying age and/or tissue-specific effects
of CB1R antagonism/inverse agonism.
In conclusion, our findings reveal age-dependent effects of CB1R
inhibition upon metabolic function in vivo. We demonstrate that CB1R
blockade leads to a marked reduction in food intake and body fat mass,
concomitant with improved insulin sensitivity and glucose tolerance, in
aged mice. Notably, these beneficial responses are either absent or less
prominent in younger animals. Moreover, we report that insulin
resistance in aged skeletal muscle and liver coincides with increased
endocannabinoid/CB1R tone. Therefore, these findings reveal a previ-
ously unknown role for CB1R in conferring aging-induced metabolic
dysfunction and identify CB1R inhibition as a potential strategy to
counteract age-associated impairments in energy homeostasis.
Experimental procedures
Animal studies
Male C57BL/6 mice at 6 weeks of age (Charles River, MA, USA) were
housed in a controlled 12 h light/dark environment and maintained
ad libitum on a standard control diet (D12450B; Research Diets, New
Brunswick, NJ, USA) until 4 months (young) or 16 months (aged) of age.
At 16 months, mice were implanted intraperitoneally with temperature
transmitters (PDT-4000 E-Mitter; Mini Mitter, Bend, OR, USA) under
general anaesthesia (mixture of isoflurane and oxygen). Mice were
allowed 14 days to recover prior to experimental treatment. Over the
next 14 days, animals were administered 3% (v/v) ethanol in dH2O
(vehicle control, n = 15) or SR141716 (10 lg g1, n = 15) by oral
gavage. During this time mice had ad libitum access to food and water,
with body mass and food intake measured daily. The average body
weights (mean  SEM) of young control and rimonabant-treated mice
at the start of experimentation were 29.18  0.45 g and
29.09  0.39 g, respectively. The average body weights of aged control
and rimonabant-treated mice at the start of experimentation were
41.15  1.43 g and 41.23  1.17 g, respectively.
Body temperature and general activity
Mice in their home cages were placed onto transponder energizers (ER-
4000 Receiver; Mini Mitter) allowing noninvasive monitoring of body
temperature and physical activity throughout the study period. The
VitalView Data Acquisition System (Mini Mitter) was used to collect the
data at 1 min intervals.
Resting metabolic rate (RMR)
RMR was determined in animals after 8–9 days of treatment using an
open-flow respiratory system described previously (Krol et al., 2003). All
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measurements took place during the light phase between 0700 and
1630. Briefly, fresh air was pumped through a sealed Perspex chamber
containing the mouse and placed within an incubator set at 30 °C,
within the thermo-neutral zone for C57BL/6 mice (Speakman & Keijer,
2012). Air was pumped through the chamber at a rate of 500–
700 mL min1 which was monitored using an Alexander Wright DM3A
flow meter. Air leaving the chamber was dried using silica gel and passed
through a gas analyser (Servomex Xentra). Gas concentrations were
measured continuously, and values recorded every 30 s for 180 min.
Oxygen consumption rates were determined using the lowest 20
consecutive values (10-min interval) and CO2 production over the
highest 20 consecutive values (10 min interval). Data (mL O2 min
1)
were converted to energy equivalents (kJ day1) using the Weir
equation and the mean respiratory quotient (RQ) for each group
(VO2*(1.106 + 3.941/RQ)*4.184*60*24)/1000). Body masses were
determined before and after each run.
Dual-energy X-ray absorptiometry (DXA) analysis
Fat mass (FM) and fat free mass (FFM) of mice were determined twice at
day 0 and day 14 using DXA (GE Medical Systems Ultrasound and BMD,
Bedford, UK). Animals were anesthetized using an isoflurane/oxygen
mixture for the duration of the scan (~3 min). Data were corrected using
a calibration formula generated by linear regression of fat content as
determined by DXA as previously described (Johnston et al., 2005).
Glucose tolerance test
Following gavage on day 10, animals received a clean cage and food was
removed from the hopper. The next morning a blood sample was taken
via the tail tip to measure basal fasting glucose concentration
(UltraTouch glucometer, LifeScan, UK). Mice were then injected
intraperitoneally with glucose (2 g kg1 body weight) and glucose
concentration determined 15, 30, 60 and 120 min after injection. Mice
were refed after the final measurement.
Analysis of blood metabolites (plasma insulin, IL-6 and
adiponectin)
Fasting plasma insulin levels were measured using a Mercodia Insulin
ELISA kit (Mercodia, Sweden) according to the manufacturer’s instruc-
tions. Analysis of plasma IL-6 and adiponectin was determined using
Mouse IL-6 and Adiponectin Quantikine ELISA Kits (both from R&D
Systems, Abingdon, UK), respectively, according to the manufacturer’s
instructions.
Dissection
On day 15, mice were culled by CO2 overdose. Half the mice received an
injection of insulin (2 mU g1) 10 min prior to cull. Careful excision of
muscle (soleus and gastrocnemius), gonadal fat and liver was performed
prior to being snap-frozen in liquid nitrogen for storage at 80 °C.
Blood serum specimens were also isolated and snap-frozen.
Muscle culture, cell/tissue treatments and analysis
Methods for culturing and treating rat L6 myotubes and their prepara-
tion for immunoblotting, RNA extraction, conventional RT–PCR and real-
time quantitative (qPCR) analysis have been previously described (Lipina
et al., 2010; Turban et al., 2012). For animal tissue, frozen tissue was
ground using a pestle and mortar prior to homogenization with ice-cold
lysis buffer. Resulting cell/tissue debris was removed from crude lysate by
centrifugation at 3000 g for 10 min at 4 °C, and the resulting
supernatant used for Western blot analysis. Proteins from cell/tissue
lysates (30 lg) were subjected to SDS–polyacrylamide gel electrophore-
sis and immunoblotted as previously described (Lipina et al., 2010;
Turban et al., 2012) with antibodies against IRS-1 (Santa Cruz, CA,
USA), phospho-IRS-1Ser307 (Merck-Millipore), PHLPP1 (Merck-Millipore,
Darmstadt, Germany), PTEN (Santa Cruz), CD68 (Santa Cruz), p85-PI3K
(Merck-Millipore), phospho-PKB/Akt (Ser473 and Thr308; New England
Biolabs, Hitchin, Herts, UK), native PKB/Akt (New England Biolabs), PGC-
1a (Abcam, Cambridge, UK), GAPDH (Sigma, Poole, Dorset, UK), insulin
receptor b-subunit (Merck-Millipore) or the catalytic subunit of PP2A
(PP2Ac, DSST, University of Dundee). Primary antibody detection was
carried out using anti-rabbit IgG-HRP or anti-mouse IgG-HRP-linked
antibody (New England Biolabs) as appropriate by ECL. Resulting band
intensities were quantified using ImageJ software (NIH, Bethseda, MD,
USA).
Statistical analysis
Data were analysed using GraphPad Prism (GraphPad, San Diego, CA,
USA). Statistical analysis was performed using one-way or two-way
ANOVA (with Bonferroni post hoc test) or Student’s unpaired t-test as
appropriate and considered statistically significant at P < 0.05. Metabolic
rate datawere analysed using ANCOVA as recommended by Tschop et al.
(Tschop et al., 2012) using body composition parameters as covariates.
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